Gene: TBC1D13
Official Full Name: TBC1 domain family member 13provided by HGNC
Gene Summary: Predicted to enable GTPase activator activity. Predicted to be involved in intracellular protein transport. Predicted to be located in cytosol and membrane. Predicted to be active in cytoplasm. [provided by Alliance of Genome Resources, Apr 2025]
Catalog Number | Product Name | Species | Gene | Passage ratio | Mycoplasma testing | Price |
---|---|---|---|---|---|---|
KO21575 | TBC1D13 Knockout cell line (HeLa) | Human | TBC1D13 | 1:3~1:6 | Negative | Online Inquiry |
KO21576 | TBC1D13 Knockout cell line (HCT 116) | Human | TBC1D13 | 1:2~1:4 | Negative | Online Inquiry |
KO21577 | TBC1D13 Knockout cell line (HEK293) | Human | TBC1D13 | 1:3~1:6 | Negative | Online Inquiry |
KO21578 | TBC1D13 Knockout cell line (A549) | Human | TBC1D13 | 1:3~1:4 | Negative | Online Inquiry |
TBC1D13 Gene Knockout Cell Lines are genetically modified cell lines specifically designed to lack the functional gene product of TBC1D13, a member of the TBC (Tre-2/Bub2/CCG) domain family of proteins involved in regulating intracellular vesicle trafficking and endosomal dynamics. By disrupting the native TBC1D13 gene, these cell lines provide researchers with a valuable tool to investigate the role of TBC1D13 in various biological processes, including autophagy, membrane traffic, and cellular signaling pathways.
The primary mechanism of action for the TBC1D13 knockout involves loss of its regulatory influence on small GTPases, which are critical for the endosomal-lysosomal pathway and overall cell homeostasis. When TBC1D13 is absent, there’s a notable alteration in vesicle transport and degradation processes, allowing scientists to unravel the intricate pathways that underlie cellular function and pathology, particularly in diseases where vesicular transport is compromised, such as neurodegeneration or cancer.
The scientific significance of TBC1D13 knockout cell lines extends beyond basic research; they hold great potential for clinical applications, particularly in understanding disease mechanisms and therapeutic target identification. By utilizing these knockout models, researchers can elucidate the implications of TBC1D13 deficiencies in disease mechanisms and screen for potential drug compounds that can restore or modulate its activity.
Compared to alternative cell lines that lack the specificity or targeted knockout capabilities, TBC1D13 Gene Knockout Cell Lines offer unmatched precision and reliability. They enable high-resolution studies of cellular processes, thereby providing a superior platform for translational research.
Investing in these cell lines not only enhances your research capabilities but also fosters innovations in therapeutic development, making them an indispensable resource for researchers and clinicians alike. Our company prides itself on its rigorous development process and expertise in creating high-quality biological products that empower scientific discovery and advancement.
Please note that all services are for research use only. Not intended for any clinical use.
If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.
There is no product in your cart. |
CD Biosynsis is a leading customer-focused biotechnology company dedicated to providing high-quality products, comprehensive service packages, and tailored solutions to support and facilitate the applications of synthetic biology in a wide range of areas.